Entropy Technologies’s Maze Therapeutics MAZE Stock Holding History

Entropy Technologies’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$338K	Buy	+11,327	New	+$297K	0.01%	767

Other funds holding MAZE

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Entropy Technologies's MAZE Position: Q2 2026 in Review

Entropy Technologies opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 11,327 shares worth $338K. The stake represents 0.01% of the portfolio and ranks #767 among its holdings.

161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

Entropy Technologies held 11,327 shares of Maze Therapeutics worth $338K as of Q2 2026.
Maze Therapeutics was a new Entropy Technologies position in Q2 2026.
Maze Therapeutics made up 0.01% of Entropy Technologies's portfolio in Q2 2026, its #767 holding.
161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.